Blueprint Medicines Corp Net Income (Loss) Attributable to Parent in USD from 2013 to Q1 2025

Taxonomy & unit
us-gaap: USD
Description
The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.
Summary
Blueprint Medicines Corp quarterly/annual Net Income (Loss) Attributable to Parent history and growth rate from 2013 to Q1 2025.
  • Blueprint Medicines Corp Net Income (Loss) Attributable to Parent for the quarter ending March 31, 2025 was $496K, a 99.4% decline year-over-year.
  • Blueprint Medicines Corp Net Income (Loss) Attributable to Parent for the twelve months ending March 31, 2025 was -$156M, a 46% increase year-over-year.
  • Blueprint Medicines Corp annual Net Income (Loss) Attributable to Parent for 2024 was -$67.1M, a 86.8% increase from 2023.
  • Blueprint Medicines Corp annual Net Income (Loss) Attributable to Parent for 2023 was -$507M, a 9.06% increase from 2022.
  • Blueprint Medicines Corp annual Net Income (Loss) Attributable to Parent for 2022 was -$558M, a 13.4% increase from 2021.
Net Income (Loss) Attributable to Parent, Trailing 12 Months (USD)
Net Income (Loss) Attributable to Parent, Quarterly (USD)
Net Income (Loss) Attributable to Parent, YoY Quarterly Growth (%)
Net Income (Loss) Attributable to Parent, Annual (USD)
Net Income (Loss) Attributable to Parent, YoY Annual Growth (%)

Blueprint Medicines Corp Quarterly Net Income (Loss) Attributable to Parent (USD)

Period TTM Value Value YoY Chg Change % Start Date End Date Report Filed
Q1 2025 -$156M $496K -$88.6M -99.4% Jan 1, 2025 Mar 31, 2025 10-Q 2025-05-01
Q4 2024 -$67.1M -$50M +$61M +55% Oct 1, 2024 Dec 31, 2024 10-K 2025-02-13
Q3 2024 -$128M -$56.3M +$77.4M +57.9% Jul 1, 2024 Sep 30, 2024 10-Q 2024-10-30
Q2 2024 -$205M -$50M +$82.8M +62.4% Apr 1, 2024 Jun 30, 2024 10-Q 2024-10-30
Q1 2024 -$288M $89.1M +$219M Jan 1, 2024 Mar 31, 2024 10-Q 2025-05-01
Q4 2023 -$507M -$111M +$47.7M +30.1% Oct 1, 2023 Dec 31, 2023 10-K 2025-02-13
Q3 2023 -$555M -$134M -$550K -0.41% Jul 1, 2023 Sep 30, 2023 10-Q 2024-10-30
Q2 2023 -$554M -$133M +$26.9M +16.9% Apr 1, 2023 Jun 30, 2023 10-Q 2024-10-30
Q1 2023 -$581M -$130M -$23.6M -22.2% Jan 1, 2023 Mar 31, 2023 10-Q 2024-10-30
Q4 2022 -$558M -$159M +$160M +50.2% Oct 1, 2022 Dec 31, 2022 10-K 2025-02-13
Q3 2022 -$718M -$133M -$15.9M -13.6% Jul 1, 2022 Sep 30, 2022 10-Q 2023-10-26
Q2 2022 -$702M -$160M -$51.3M -47.3% Apr 1, 2022 Jun 30, 2022 10-Q 2023-10-26
Q1 2022 -$650M -$106M -$6.29M -6.3% Jan 1, 2022 Mar 31, 2022 10-Q 2023-10-26
Q4 2021 -$644M -$319M -$233M -272% Oct 1, 2021 Dec 31, 2021 10-K 2024-02-15
Q3 2021 -$411M -$117M -$751M -118% Jul 1, 2021 Sep 30, 2021 10-Q 2022-11-01
Q2 2021 $340M -$108M +$15M +12.2% Apr 1, 2021 Jun 30, 2021 10-Q 2022-11-01
Q1 2021 $325M -$99.7M +$11.2M +10.1% Jan 1, 2021 Mar 31, 2021 10-Q 2022-11-01
Q4 2020 $314M -$85.7M -$19.3M -29.2% Oct 1, 2020 Dec 31, 2020 10-K 2023-02-16
Q3 2020 $333M $634M +$728M Jul 1, 2020 Sep 30, 2020 10-Q 2021-10-28
Q2 2020 -$395M -$123M -$23.8M -23.9% Apr 1, 2020 Jun 30, 2020 10-Q 2021-10-28
Q1 2020 -$371M -$111M -$23.5M -26.9% Jan 1, 2020 Mar 31, 2020 10-Q 2021-10-28
Q4 2019 -$348M -$66.3M +$14M +17.4% Oct 1, 2019 Dec 31, 2019 10-K 2020-02-13
Q3 2019 -$362M -$94.3M -$21.6M -29.6% Jul 1, 2019 Sep 30, 2019 10-Q 2020-10-29
Q2 2019 -$340M -$99.7M -$72.6M -269% Apr 1, 2019 Jun 30, 2019 10-Q 2020-10-29
Q1 2019 -$268M -$87.4M -$30.9M -54.6% Jan 1, 2019 Mar 31, 2019 10-Q 2020-10-29
Q4 2018 -$237M -$80.3M -$31.3M -63.8% Oct 1, 2018 Dec 31, 2018 10-K 2020-02-13
Q3 2018 -$205M -$72.7M -$35M -92.9% Jul 1, 2018 Sep 30, 2018 10-K 2020-02-13
Q2 2018 -$170M -$27M +$6.36M +19% Apr 1, 2018 Jun 30, 2018 10-K 2020-02-13
Q1 2018 -$177M -$56.5M -$28.6M -102% Jan 1, 2018 Mar 31, 2018 10-K 2020-02-13
Q4 2017 -$148M -$49M -$27.8M -131% Oct 1, 2017 Dec 31, 2017 10-K 2019-02-26
Q3 2017 -$120M -$37.7M -$20.9M -124% Jul 1, 2017 Sep 30, 2017 10-K 2019-02-26
Q2 2017 -$99.5M -$33.4M -$14.5M -76.8% Apr 1, 2017 Jun 30, 2017 10-K 2019-02-26
Q1 2017 -$85M -$28M -$12.5M -80.5% Jan 1, 2017 Mar 31, 2017 10-K 2019-02-26
Q4 2016 -$72.5M -$21.3M -$5.69M -36.5% Oct 1, 2016 Dec 31, 2016 10-K 2018-02-21
Q3 2016 -$66.8M -$16.8M -$4.19M -33.2% Jul 1, 2016 Sep 30, 2016 10-K 2018-02-21
Q2 2016 -$62.6M -$18.9M -$5.91M -45.6% Apr 1, 2016 Jun 30, 2016 10-K 2018-02-21
Q1 2016 -$56.7M -$15.5M -$3.93M -34% Jan 1, 2016 Mar 31, 2016 10-K 2018-02-21
Q4 2015 -$52.8M -$15.6M -$1.11M -7.65% Oct 1, 2015 Dec 31, 2015 10-K 2017-03-09
Q3 2015 -$51.7M -$12.6M -$2.14M -20.4% Jul 1, 2015 Sep 30, 2015 10-K 2017-03-09
Q2 2015 -$49.5M -$13M -$4.69M -56.6% Apr 1, 2015 Jun 30, 2015 10-K 2017-03-09
Q1 2015 -$44.8M -$11.6M -$4.55M -64.7% Jan 1, 2015 Mar 31, 2015 10-K 2017-03-09
Q4 2014 -$40.3M -$14.5M Oct 1, 2014 Dec 31, 2014 10-K 2016-03-11
Q3 2014 -$10.5M Jul 1, 2014 Sep 30, 2014 10-K 2016-03-11
Q2 2014 -$8.29M Apr 1, 2014 Jun 30, 2014 10-K 2016-03-11
Q1 2014 -$7.03M Jan 1, 2014 Mar 31, 2014 10-K 2016-03-11

Blueprint Medicines Corp Annual Net Income (Loss) Attributable to Parent (USD)

Period Value YoY Chg Change % Start Date End Date Report Filed
2024 -$67.1M +$440M +86.8% Jan 1, 2024 Dec 31, 2024 10-K 2025-02-13
2023 -$507M +$50.5M +9.06% Jan 1, 2023 Dec 31, 2023 10-K 2025-02-13
2022 -$558M +$86.6M +13.4% Jan 1, 2022 Dec 31, 2022 10-K 2025-02-13
2021 -$644M -$958M -305% Jan 1, 2021 Dec 31, 2021 10-K 2024-02-15
2020 $314M +$662M Jan 1, 2020 Dec 31, 2020 10-K 2023-02-16
2019 -$348M -$111M -46.9% Jan 1, 2019 Dec 31, 2019 10-K 2022-02-17
2018 -$237M -$88.5M -59.8% Jan 1, 2018 Dec 31, 2018 10-K 2021-02-17
2017 -$148M -$75.6M -104% Jan 1, 2017 Dec 31, 2017 10-K 2020-02-13
2016 -$72.5M -$19.7M -37.4% Jan 1, 2016 Dec 31, 2016 10-K 2019-02-26
2015 -$52.8M -$12.5M -31% Jan 1, 2015 Dec 31, 2015 10-K 2018-02-21
2014 -$40.3M -$19.4M -92.6% Jan 1, 2014 Dec 31, 2014 10-K 2017-03-09
2013 -$20.9M Jan 1, 2013 Dec 31, 2013 10-K 2016-03-11
* An asterisk sign (*) next to the value indicates that the value is likely invalid.